| [1] |
Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21[J]. Science, 1990, 250(4988):1684-1689.
|
| [2] |
Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer[J]. Hum Mol Genet, 2001, 10(7):705-713.
|
| [3] |
Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention[J]. Science, 2014, 343(6178):1466-1470.
|
| [4] |
《BRCA数据解读中国专家共识》编写组. BRCA数据解读中国专家共识[J]．中华病理学杂志，2017，46(5):293-297.
|
| [5] |
Sun J, Meng H, Yao L, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients[J]. Clin Cancer Res, 2017, 23(20):6113-6119.
|
| [6] |
Li J, Jing R, Wei H, et al. Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer [EB/OL]. [2018-05-01].
URL
|
| [7] |
Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer[J]. Breast Cancer Res Treat, 2016, 158(3):455-462.
|
| [8] |
Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study[J]. Lancet Oncol, 2018, 19(2):169-180.
|
| [9] |
Zhao W, Steinfeld JB, Liang F, et al. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing[J]. Nature, 2017, 550(7676):360-365.
|
| [10] |
Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial [J]. Nat Med, 2018, 24(5):628-637.
|
| [11] |
Hahnen E, Lederer B, Hauke J, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial[J]. JAMA Oncol, 2017, 3(10):1378-1385.
|
| [12] |
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6):523-533.
|
| [13] |
Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation[J]. N Engl J Med, 2001, 345(3):159-164.
|
| [14] |
Yamauchi H, Takei J. Management of hereditary breast and ovarian cancer[J]. Int J Clin Oncol, 2017, 23(1):45-51.
|
| [15] |
Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group[J]. J Clin Oncol, 2004, 22(6):1055-1062.
|
| [16] |
Contant CM, Menke-Pluijmers MB, Seynaeve C, et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation[J]. Eur J Surg Oncol, 2002, 28(6):627-632.
|
| [17] |
Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers [J]. J Clin Oncol, 2004, 22(12): 2328-2335.
|
| [18] |
Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project[J]. J Clin Oncol, 2005, 23(19):4275-4286.
|
| [19] |
Wong SM, Freedman RA, Sagara Y, et al. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer[J]. Ann Surg, 2016, 265(3):581-589.
|
| [20] |
Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients[J]. J Natl Cancer Inst, 2010, 102(6):401-409.
|
| [21] |
Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer[J]. Cochrane Database Syst Rev, 2018, 4(1):CD002748.
|
| [22] |
Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer[J]. N Engl J Med, 2016, 374(5):454-468.
|
| [23] |
Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer[J]. J Clin Oncol, 2006, 24(16): 2437-2443.
|
| [24] |
Metcalfe K, Lynch HT, Ghadirian P, et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers[J]. Breast Cancer Res Treat, 2011, 127(1):287-296.
|
| [25] |
Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis[J]. Breast Cancer Res Treat, 2014, 144(3):443-455.
|
| [26] |
Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination[J]. JAMA, 2004, 292(11): 1317-1325.
|
| [27] |
Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging[J]. J Clin Oncol, 2011, 29(13): 1664-1669.
|
| [28] |
Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging[J]. JAMA, 2006, 295(20):2374-2384.
|
| [29] |
Sardanelli F, Podo F, Santoro F, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results[J]. Invest Radiol, 2011, 46(2):94-105.
|
| [30] |
邵志敏，徐兵河，任国胜．中国乳腺癌患者BRCA1/2基因检测与临床应用专家共识[J]. 中国癌症杂志，2018，28(10):787-800.
|
| [31] |
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med, 2013, 368(13):1199-1209.
|
| [32] |
林健，贾淞淋，方敏，等．早期乳腺癌患者循环肿瘤细胞TP53、磷脂酰肌醇-3激酶基因突变分析及其与患者临床病理特征的相关性[J]．中国临床医学，2018，25 (2):210-216.
|
| [33] |
Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J]. Nat Genet, 2013, 45(12):1439-1445.
|
| [34] |
Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2016, 34(25):2961-2968.
|
| [35] |
Weir HM, Bradbury RH, Lawson M, et al. AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models[J]. Cancer Res, 2016, 76(11): 3307-3318.
|
| [36] |
Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer[J]．N Engl J Med, 2015, 373(3): 209-219.
|
| [37] |
Chen L, Yang L, Yao L, et a1. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients[J]. Nat Commun, 2018, 9(1):1357.
|
| [38] |
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med, 2013, 368(13):1199-1209.
|
| [39] |
Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2018, 19(1): 87-100.
|
| [40] |
Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial[J]. Lancet, 2002, 359(9324): 2131-2139.
|
| [41] |
Dowsett M, Cuzick J, Wale C, et a1. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study[J]. J Clin Oncol, 2010, 28(11):1829-1834.
|